

225Ac-PSMA-617 for PSMA-targeted α -radiation therapy of metastatic castration-resistant prostate cancer

C Kratochwil, F Bruchertseifer, FL Giesel, M Weis, FA Verburg, F Mottaghy, K Kopka...

Journal of Nuclear Medicine, 2016 • Soc Nuclear Med

[SHOW MORE](#) ▾

[☆ Save](#) [🔗 Cite](#) [Cited by 861](#) [Related articles](#) [All 12 versions](#)

Showing the best result for this search. [See all results](#)

UH & EURATOM Ex. 2030-001
Fusion v. Universität Heidelberg, et al.
IPR2023-00551

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer

M Weineisen, J Simecek, M Schottelius, M Schwaiger, HJ Wester

EJNMMI research, 2014 • Springer

[SHOW MORE](#) ▾

[☆ Save](#) [🔗 Cite](#) [Cited by 207](#) [Related articles](#) [All 13 versions](#)

Showing the best result for this search. [See all results](#)

UH & EURATOM Ex. 2030-002
Fusion v. Universität Heidelberg, et al.
IPR2023-00551

68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies

M Weineisen, M Schottelius, J Simecek, RP Baum, A Yildiz, S Beykan, HR Kulkarni...

Journal of Nuclear Medicine, 2015 • Soc Nuclear Med

[SHOW MORE](#) ▾

☆ Save  Cite Cited by 536 Related articles All 11 versions

Showing the best result for this search. [See all results](#)

UH & EURATOM Ex. 2030-003
Fusion v. Universität Heidelberg, et al.
IPR2023-00551

213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer

K Chatalic, J Nonnekens, F Bruchertseifer, A Morgenstern, M Schottelius, H Wester...

2016 • Soc Nuclear Med

[SHOW MORE](#) ▾

☆ Save  Cite Cited by 2 Related articles All 2 versions

Showing the best result for this search. [See all results](#)

Preclinical Evaluation of the α -Particle Generator Nuclide ^{225}Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors

M Miederer, G Henriksen, A Alke, I Mossbrugger, L Quintanilla-Martinez...

Clinical Cancer Research, 2008 • AACR

Abstract

[SHOW MORE](#) ▾

☆ Save  Cite Cited by 153 Related articles All 6 versions

Showing the best result for this search. [See all results](#)

UH & EURATOM Ex. 2030-005
Fusion v. Universität Heidelberg, et al.
IPR2023-00551

... trial of targeted alpha-particle therapy with actinium-225 (225Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute ...

JG Jurcic, MY Levy, JH Park, F Ravandi, AE Perl... - **Blood**, 2016 - Elsevier

Background: 225 Ac-lintuzumab is a radioimmunoconjugate composed of 225 Ac (t ½ =10 days), which emits 4 α-particles, linked to a humanized anti-CD33 monoclonal antibody. Short-...

☆ Save Cite Cited by 47 Related articles All 3 versions

Investigational CD33-targeted therapeutics for acute myeloid leukemia

RB Walter - Expert opinion on investigational drugs, 2018 - Taylor & Francis

... If a CR or CR with incomplete **blood** count recovery (CRi) was obtained, extension treatment every 3 weeks at 5 or 10 µg/kg could be given. Among all 131 patients, 30- and 60-day ...

☆ Save Cite Cited by 83 Related articles All 3 versions

The role of targeted therapy in the management of patients with AML

AE Perl - **Blood** advances, 2017 - ashpublications.org

... Instead, nearly all "deep" marrow responses were termed modified complete remission with incomplete **blood** count recovery (CRi) because transfusion independence was not required...

☆ Save Cite Cited by 108 Related articles All 11 versions

Development of targeted alpha particle therapy for solid tumors

NK Tafreshi, ML Doligalski, CJ Tichacek, DN Pandya... - **Molecules**, 2019 - mdpi.com

... , it has been proposed that nanoparticles or liposomes could be used to sequester decaying daughter products that would otherwise be released to freely circulate in the **blood** because ...

☆ Save Cite Cited by 90 Related articles All 11 versions

New perspectives in treating acute myeloid leukemia: driving towards a patient-tailored strategy

F Andreozzi, F Massaro, S Wittnebel... - **International journal of ...**, 2022 - mdpi.com

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who ...

☆ Save Cite Cited by 13 Related articles All 8 versions

What are the latest advancements in acute myeloid leukemia therapy?

A Goodman, ED Ball - **Future Oncology**, 2017 - Future Medicine

COmmEntaRY Goodman & Ball future science group proceed with consolidation therapy. The findings from a Phase III randomized trial evaluating CPX-351 versus 7+ 3 induction for ...

☆ Save Cite Cited by 2 Related articles All 4 versions

Overview of the most promising radionuclides for targeted alpha therapy: The "hopeful eight"

R Eychenne, M Chérel, F Haddad, F Guérard... - **Pharmaceutics**, 2021 - mdpi.com

... In addition to a fast clearance from **blood**, the biodistribution profile of 225 Ac-DOTA complex showed a low uptake in liver and bones, target organs of free 225 Ac, which validated a ...

☆ Save Cite Cited by 65 Related articles All 11 versions

Evaluation of the Effect of Chelating Arms and Carrier Agents on the Radiotoxicity of TAT Agents

S Farzipour, Z Shaghaghi, M Raeispour... - **Current ...**, 2023 - ingentaconnect.com

... Many approaches have been developed to control the daughter fate, including: i) Extraction and their removal from **blood** and tissue using specific ligands ii) usage of diffusing α-emitter ...

☆ Save Cite Cited by 3 Related articles All 3 versions

UH & EURATOM Ex. 2030-006
Fusion v. Universität Heidelberg, et al.
IPR2023-00551

Targeted alpha therapy and Nanocarrier approach

M Silindir-Gunay, M Karpuz, AY Ozer - Cancer Biotherapy & ..., 2020 - liebertpub.com

... surface properties and remaining longer in **blood** circulation, thus the possible side-effects of ... in the tumor area due to their slower **blood** elimination, higher area under the curve, longer ...

☆ Save Cite Cited by 18 Related articles All 5 versions

The design, synthesis, and evaluation of radiopharmaceuticals for actinium-225

V Brown - 2021 - summit.sfu.ca

... Antibody fragments have superior tumor penetration depth and rapid **blood** clearance while maintaining high receptor affinity^{24,27,28}. However, similar to peptides, rapid **blood** ...

☆ Save Cite Related articles

Ac-225-DOTATOC-an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors

C Kratochwil, F Bruchertseifer, F Giesel, C Apostolidis, U Haberkorn, A Morgenstern

2015 • Soc Nuclear Med

[SHOW MORE](#) ▾

[☆ Save](#) [🔗 Cite](#) [Cited by 45](#) [Related articles](#) [All 2 versions](#)

Showing the best result for this search. [See all results](#)

UH & EURATOM Ex. 2030-008
Fusion v. Universität Heidelberg, et al.
IPR2023-00551